Evaluation of Intraperitoneal Instillation Combined with Port-Site Infiltration of 0.5% Bupivacaine for Postoperative Pain Management in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial

Background: Postoperative pain after laparoscopic cholecystectomy is predominantly visceral in the first 24 hours and is conventionally managed with systemic analgesics that carry opioid-related adverse effects. Intraperitoneal instillation of a long-acting local anaesthetic targets visceral pain at its source. Aims and Objective: To evaluate the efficacy and safety of intraperitoneal instillation of 0.5% bupivacaine combined with port-site infiltration in reducing postoperative pain and analgesic requirement after elective laparoscopic cholecystectomy. Materials and Methods: In this prospective randomized controlled trial, 120 adults (American Society of Anesthesiologists class I–II) undergoing elective laparoscopic cholecystectomy were randomized to receive 20 mL of 0.5% bupivacaine instilled intraperitoneally over the gallbladder bed, hepatic surface and subdiaphragmatic space together with 10 mL infiltrated at the port sites at the end of surgery (n=60), or standard care without local anaesthetic (n=60). Patients and outcome assessors were blinded to allocation. Pain was assessed on a visual analogue scale (VAS) at 6, 12 and 24 hours. Time to first rescue analgesia, 24-hour opioid, non-steroidal anti-inflammatory drug (NSAID) and paracetamol consumption, adverse effects and satisfaction were recorded. Results: Mean VAS was lower in the bupivacaine group at 6 h (3.43±1.75 vs 6.88±0.99), 12 h (4.27±1.22 vs 7.82±1.46) and 24 h (3.80±0.40 vs 6.38±0.52; all p<0.001). Rescue analgesia was required by 15.0% versus 100% of patients (p<0.001), the time to first rescue analgesia among those who required it was longer (7.14±2.25 vs 1.70±0.74 h; p<0.001), and 24-hour opioid consumption was lower (5.83±16.19 vs 40.83±19.51 mg; p<0.001). Nausea, vomiting and shoulder pain were less frequent and satisfaction was higher (p=0.014) with bupivacaine; no hypotension, arrhythmia or local anaesthetic toxicity occurred. Conclusion: Intraperitoneal instillation of 0.5% bupivacaine combined with port-site infiltration is a simple, safe and effective addition to multimodal analgesia after laparoscopic cholecystectomy.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-26
DOI
https://doi.org/10.5281/zenodo.23658758
Primary Topic
Anesthesia and Pain Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of Intraperitoneal Instillation Combined with Port-Site Infiltration of 0.5% Bupivacaine for Postoperative Pain Management in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial

Pankaj Kumar Saunakiya, Surya Prakash, Saurabh Purohit, Anmol Gupta
Zenodo (CERN European Organization for Nuclear Research)
Anesthesia and Pain Management
article

Evaluation of Intraperitoneal Instillation Combined with Port-Site Infiltration of 0.5% Bupivacaine for Postoperative Pain Management in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial

Pankaj Kumar Saunakiya, Surya Prakash, Saurabh Purohit, Anmol Gupta
article en

Abstract

Background: Postoperative pain after laparoscopic cholecystectomy is predominantly visceral in the first 24 hours and is conventionally managed with systemic analgesics that carry opioid-related adverse effects. Intraperitoneal instillation of a long-acting local anaesthetic targets visceral pain at its source. Aims and Objective: To evaluate the efficacy and safety of intraperitoneal instillation of 0.5% bupivacaine combined with port-site infiltration in reducing postoperative pain and analgesic requirement after elective laparoscopic cholecystectomy. Materials and Methods: In this prospective randomized controlled trial, 120 adults (American Society of Anesthesiologists class I–II) undergoing elective laparoscopic cholecystectomy were randomized to receive 20 mL of 0.5% bupivacaine instilled intraperitoneally over the gallbladder bed, hepatic surface and subdiaphragmatic space together with 10 mL infiltrated at the port sites at the end of surgery (n=60), or standard care without local anaesthetic (n=60). Patients and outcome assessors were blinded to allocation. Pain was assessed on a visual analogue scale (VAS) at 6, 12 and 24 hours. Time to first rescue analgesia, 24-hour opioid, non-steroidal anti-inflammatory drug (NSAID) and paracetamol consumption, adverse effects and satisfaction were recorded. Results: Mean VAS was lower in the bupivacaine group at 6 h (3.43±1.75 vs 6.88±0.99), 12 h (4.27±1.22 vs 7.82±1.46) and 24 h (3.80±0.40 vs 6.38±0.52; all p<0.001). Rescue analgesia was required by 15.0% versus 100% of patients (p<0.001), the time to first rescue analgesia among those who required it was longer (7.14±2.25 vs 1.70±0.74 h; p<0.001), and 24-hour opioid consumption was lower (5.83±16.19 vs 40.83±19.51 mg; p<0.001). Nausea, vomiting and shoulder pain were less frequent and satisfaction was higher (p=0.014) with bupivacaine; no hypotension, arrhythmia or local anaesthetic toxicity occurred. Conclusion: Intraperitoneal instillation of 0.5% bupivacaine combined with port-site infiltration is a simple, safe and effective addition to multimodal analgesia after laparoscopic cholecystectomy.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 10%
Anesthesia and Pain Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon